Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

13.85 -2.30 (-14.24%)
Streaming Delayed Price Updated: 2:38 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Telix Pharmaceuticals Limited - American Depositary Shares

Anne Whitaker Appointed as Non-Executive Director
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
From Telix Pharmaceuticals Limited
Via GlobeNewswire
ARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®
From Telix ARTMS, Inc.
Via GlobeNewswire
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Adds Lead-212 Isotope Production Capability
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
From Telix Pharmaceuticals Limited
Via GlobeNewswire
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Illuccix® Approved in the United Kingdom
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Completes Acquisition of RLS (USA) Inc.
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Illuccix® Receives European Approval
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.